Skip navigation

SMA screening with HorizonTM

With new treatments for spinal muscular atrophy (SMA), screening isn’t just knowledge. Carrier screening means informed decisions and the opportunity for earlier, more effective, treatment; it means the chance to change the course of a child’s life.


Horizon’s trusted technology includes next-generation sequencing (NGS) and enhanced SNP-based technology, providing comprehensive screening to detect SMA carriers.

A Fresh Perspective on DNA

Learn about SMA and the need for screening through Lola’s story

“It went from, ‘I’m going to coach her soccer or softball team’… to ‘I’m going to coach her how to roll around in a wheelchair and maybe one day she’ll walk.”

Brady Camp

Father of Lola (born with SMA)

View Our Webinar: Enabling Better Outcomes Through SMA Carrier Screening

With the availability of SMA gene therapies, carrier screening can lead to earlier treatment and better outcomes. Learn how you can make a difference by offering carrier screening to your patients.


Hear from Alecia, whose daughter Lola was diagnosed with SMA at 5 1⁄2 months of age, and Dr. Barry Byrne, a pediatric cardiologist and gene therapy expert at the University of Florida. In the webinar, they discuss how carrier screening can impact the SMA treatment timeline and change the course of a child’s life.

  • Alecia Camp
    Mother of Lola who was diagnosed with SMA at 5 months of age
  • Barry Byrne, MD
    Pediatric cardiologist specializing in gene therapy at the University of Florida

Learn More About Horizon

All carrier screening is not equal, and choosing the right test for your patients is critical. Traditional screening misses ~60% of patients Horizon identifies as at-risk SMA carriers. Learn how Horizon leverages advanced technology and unmatched support to help you and your patients.

Learn more